Compare
Xilio Therapeutics, Inc. vs Cumberland Pharmaceuticals Inc vs Aquestive Therapeutics, Inc. vs Biofrontera Inc.
| Latest fiscal year | Xilio Therapeutics, Inc. XLO | Cumberland Pharmaceuticals Inc CPIX | Aquestive Therapeutics, Inc. AQST | Biofrontera Inc. BFRI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $43.77M | $44.52M | $44.55M | $41.70M |
| Revenue growth (YoY) | +589.9% | +17.6% | -22.6% | +11.7% |
| Gross margin | n/a | 85.0% (computed) | 58.3% (computed) | n/a |
| Operating margin | -95.9% | -6.3% | -159.5% | -27.2% |
| Net margin | -80.1% | -6.4% | -188.1% | -25.3% |
| Net income | -$35.04M | -$2.84M | -$83.78M | -$10.54M |
| EPS (Diluted) | -$4.19 | -$0.19 | -$0.78 | -$1.04 |
| Operating cash flow | -$4.99M | $4.93M | -$52.43M | -$13.36M |
| Free cash flow | -$5.51M | $4.83M | -$52.99M | -$13.36M |
| Cash & equivalents | $137.53M | $11.44M | n/a | $6.39M |
| Total assets | $154.69M | $76.82M | $160.43M | $28.56M |
| Total liabilities | $119.41M | $52.28M | $194.09M | $18.08M |
| Shareholders' equity | $35.27M | $24.88M | -$33.66M | $10.48M |
| Return on year-end equity | -99.3% | -11.4% | n/a | -100.5% |
| Shares outstanding | 4.53M | 14.96M | 122.04M | 11.65M |
Revenue, most recent five fiscal years
| Fiscal year | Xilio Therapeutics, Inc. | Cumberland Pharmaceuticals Inc | Aquestive Therapeutics, Inc. | Biofrontera Inc. |
|---|---|---|---|---|
| Latest | $43.77M Ended 2025-12-31 | $44.52M Ended 2025-12-31 | $44.55M Ended 2025-12-31 | $41.70M Ended 2025-12-31 |
| 1 year earlier | $6.34M Ended 2024-12-31 | $37.87M Ended 2024-12-31 | $57.56M Ended 2024-12-31 | $37.32M Ended 2024-12-31 |
| 2 years earlier | n/a | $39.55M Ended 2023-12-31 | $50.58M Ended 2023-12-31 | $34.07M Ended 2023-12-31 |
| 3 years earlier | n/a | $42.01M Ended 2022-12-31 | $47.68M Ended 2022-12-31 | $28.67M Ended 2022-12-31 |
| 4 years earlier | n/a | $35.05M Ended 2021-12-31 | $50.83M Ended 2021-12-31 | $24.10M Ended 2021-12-31 |